← Back to Search

Neural Interface System

BrainGate2 Neural Interface for Quadriplegia (BrainGate2 Trial)

N/A
Recruiting
Led By Leigh R Hochberg, M.D., PH.D.
Research Sponsored by Leigh R. Hochberg, MD, PhD.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
Complete or incomplete tetraplegia (quadriplegia)
Must not have
Chronic oral or intravenous steroids or immunosuppressive therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This study is evaluating whether people with tetraplegia may be able to control a computer cursor and other assistive devices with their thoughts.

Who is the study for?
This trial is for people with conditions like ALS, muscular dystrophy, or spinal cord injuries that have led to tetraplegia. Participants must live close to the study site and be able to use a computer screen even with vision correction. They can't join if they're on chronic steroids/immunosuppressants or have other serious diseases.
What is being tested?
The BrainGate2 study tests whether individuals with tetraplegia can control a computer cursor and other devices using their thoughts after having a sensor placed in their brain's motor cortex.
What are the potential side effects?
Potential side effects are not detailed here but may include risks associated with surgical implantation of the device, such as infection, bleeding, or damage to surrounding brain tissue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a diagnosed condition affecting my nerves or muscles, such as ALS or muscular dystrophy.
Select...
I have paralysis affecting all four limbs.
Select...
I have a condition affecting my nerves or muscles, like ALS or muscular dystrophy.
Select...
I have paralysis that affects all four of my limbs.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not on long-term steroids or drugs that weaken my immune system.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BrainGateExperimental Treatment1 Intervention
BrainGate Neural Interface System

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The Brain-Computer Interface (BCI) is a promising treatment for quadriplegia that translates neural signals directly from the brain into commands to control external devices, such as computer cursors or robotic limbs. This technology leverages the intact neural pathways in the brain to bypass damaged spinal cord regions, allowing patients to interact with their environment through thought alone. This is particularly significant for quadriplegia patients as it offers a potential pathway to regain independence and improve quality of life by enabling control over assistive devices. Other common treatments include physical therapy, occupational therapy, and the use of assistive technologies, all aimed at maximizing functional abilities and enhancing daily living activities.
Interventions to Improve Movement and Functional Outcomes in Adult Stroke Rehabilitation: Review and Evidence Summary.Restoring walking after spinal cord injury: operant conditioning of spinal reflexes can help.Therapeutic synergism in the treatment of post-stroke arm paresis utilizing botulinum toxin, robotic therapy, and constraint-induced movement therapy.

Find a Location

Who is running the clinical trial?

US Department of Veterans AffairsFED
875 Previous Clinical Trials
498,394 Total Patients Enrolled
6 Trials studying Quadriplegia
92 Patients Enrolled for Quadriplegia
Leigh R. Hochberg, MD, PhD.Lead Sponsor
3 Previous Clinical Trials
6 Total Patients Enrolled
3 Trials studying Quadriplegia
6 Patients Enrolled for Quadriplegia
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
360 Previous Clinical Trials
182,176 Total Patients Enrolled
3 Trials studying Quadriplegia
6 Patients Enrolled for Quadriplegia
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,382 Previous Clinical Trials
652,319 Total Patients Enrolled
4 Trials studying Quadriplegia
137 Patients Enrolled for Quadriplegia
Leigh R Hochberg, M.D., PH.D.Principal InvestigatorMassachusetts General Hospital
Leigh R Hochberg, M.D., Ph.D.Principal InvestigatorMassachusetts General Hospital

Media Library

BrainGate2 (Neural Interface System) Clinical Trial Eligibility Overview. Trial Name: NCT00912041 — N/A
Quadriplegia Research Study Groups: BrainGate
Quadriplegia Clinical Trial 2023: BrainGate2 Highlights & Side Effects. Trial Name: NCT00912041 — N/A
BrainGate2 (Neural Interface System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00912041 — N/A
~13 spots leftby Sep 2038